Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...
Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...
Vor Biopharma Inc. (NYSE:VOR – Free Report) – Equities research analysts at Wedbush issued their Q1 2026 earnings estimates for Vor Biopharma in a research report issued on Thursday, May 8th. Wedbush ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback